Abbott Laboratories vs ARCELLX, INC. · ABT FY2025 (ended 2025-12-31) vs ACLX FY2025 (ended 2025-12-31) · computed from SEC XBRL filings
| Metric | ABT FY2025 · 2025-12-31 | ACLX FY2025 · 2025-12-31 |
|---|---|---|
| Revenue | $44.33B | $22.3M |
| Revenue growth (YoY) | 5.7% | -79.4% |
| Operating margin | 18.2% | -1135.6% |
| Net margin | 14.7% | -1027.3% |
| FCF margin | 16.7% | -953.9% |
| Capex % of revenue | 4.9% | 10.4% |
Want ABT against its full peer set, not just ACLX?
A CompsDesk subscription covers unlimited packs: up to 12 peers you choose, up to 19 metrics (6 core guaranteed), trends for every filed year (up to five), the subject's figures cited to their SEC tag, form and period with every company identified by its CIK — PDF-ready HTML + CSV, generated on demand.
Each column is that company's OWN annual period, labeled above with its fiscal year and period end. ACLX's is the annual period ending closest to ABT's 2025-12-31: where ACLX has already filed a fiscal year ABT has not, this comparison uses ACLX's matching period rather than that later one. Fiscal calendars differ across companies, so two matching fiscal years can still end months apart, on either side of each other: past 183 days no winner is called, and past 400 days the column reads "n.m." throughout and nothing is compared across it. Green = better on that metric where direction is unambiguous. Source: SEC EDGAR XBRL (10-K). "n/a" = not disclosed under mapped tags; never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.